Select a medication above to begin.
Hepcludex (bulevirtide-gmod)
bulevirtide
Black Box Warnings .
Hepatitis D and B Exacerbation
severe acute exacerbations may occur after bulevirtide D/C; patients with cirrhosis may be at increased risk of more severe flares or progression to hepatic decompensation; monitor hepatic function closely, including HBV DNA and HDV RNA viral load, for at least 6 months after D/C tx; resume antiviral tx if needed
Adult Dosing .
Dosage forms: INJ
Special Note
- [drug name clarification]
- Info: nonproprietary name = bulevirtide-gmod
hepatitis D infection, chronic
- [8.5 mg SC qd]
- Info: for patients without cirrhosis or with compensated cirrhosis
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [see below]
- Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: not defined
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.